Drugs / Efepoetin Alfa
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06490939 | Oct 2024 → Mar 2025 | — | Genexine, Inc. | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06466785 | Jan 2024 → Jun 2027 expected | anemia due to chronic disorder | Genexine, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT04155125 | Jul 2020 → Mar 2022 | anemia due to chronic disorder | PT Kalbe Genexine Biologics | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Efepoetin Alfa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06466785 ↗ |
| Known as | Efepoetina alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594471 ↗ |
| Known as | Efepoetine alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594471 ↗ |
| Known as | GX-E2 | “Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine” NCT06466785 ↗ |
| Known as | GX-E4 | “This study is to objectively evaluate pharmacokinetics as well as pharmacodynamic responses after a single intravenous administration of the Efepoetin alfa, GX-E4, in healthy...” NCT06490939 ↗ |
| Action | Activate | “Erythropoietin receptor agonist” CHEMBL4594471 ↗ |
| Modality | Protein / enzyme biologic | “Efepoetin alfa (Epoetin-Fc fusion protein, GX-E2 or GX-E4,) is a novel long-acting erythropoietin-hybrid fragment crystallizable (Fc) fusion protein developed by Genexine” NCT06466785 ↗ |
| Route | Subcutaneous | “subcutaneous efepoetin alfa” NCT04155125 ↗ |
| Target | EPOR | “Erythropoietin receptor agonist” CHEMBL4594471 ↗ |